

RECOMBINANT VACCINE AGAINST RABBIT HAEMORRHAGIC DISEASE

Authors

Prof. Bogusław Szewczyk
Beata Gromadzka
Andrzej Fitzner
Andrzej Kęsy

Intercollegiate Faculty of Biotechnology
University of Gdańsk
Medical University of Gdańsk

Commercialization opportunities



- ➔ Licensing agreement
- ➔ Transfer of ownership
- ➔ Spin off

IP Status



The invention was submitted for patenting according to Polish (P.376122) procedures.

Implementation progress



TRL 4
Technology validated in
laboratory conditions

Rabbit haemorrhagic disease (RHD) is a viral disease which poses a serious threat for both rabbit farmers and rabbit owners, due to its contagiousness and high mortality of infected animals. Aforementioned factors necessitate culling of not only actually infected individuals, but also animals suspected of contact with infected ones, resulting in severe economic losses in farming industry.

Despite numerous research efforts focused on recombinant RHD vaccines, continuing need for effective marker vaccines exists among veterinary services, farmers, breeders and rabbit owners. Such a vaccine should not only provide effective protection of animals, but also allow users to distinguish between infected animals and vaccinated individuals.

Technology developed by scientists from University of Gdańsk allows for production of recombinant capsid protein with haemagglutinating and antigenic properties, capable of forming pseudoviral (VLP) particles and thus stimulating production of antibodies in vaccinated animals. In addition, marker properties of developed vaccine provide effective means of immunological differentiation between already vaccinated animals and those infected with RHD.

Technology related to offer no. 029/2017/1

Technology Transfer Office



biuro@ctt.ug.edu.pl



58 523 33 74
58 523 33 75



ul. Jana Bażyńskiego 1a
80-309 Gdańsk